618092-72-1 Usage
Chemical Class
Pyrazole derivatives
Physical Appearance
White to off-white powder
Industry Usage
Pharmaceutical industry
Therapeutic Applications
Potential use in various medical fields
Anti-Inflammatory Properties
Studied for its ability to reduce inflammation
Analgesic Properties
Investigated for its pain-relieving capabilities
Anticancer Properties
Researched for potential cancer treatment applications
COX-2 Inhibition
Potential use as a COX-2 inhibitor
Neurodegenerative Disease Treatment
Investigated for treatment of Alzheimer's and Parkinson's diseases
Enzyme Inhibition
Shown potential as an inhibitor of enzymes involved in blood pressure and kidney function regulation
Ongoing Research
Further studies to determine full range of therapeutic applications
Check Digit Verification of cas no
The CAS Registry Mumber 618092-72-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,1,8,0,9 and 2 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 618092-72:
(8*6)+(7*1)+(6*8)+(5*0)+(4*9)+(3*2)+(2*7)+(1*2)=161
161 % 10 = 1
So 618092-72-1 is a valid CAS Registry Number.
618092-72-1Relevant articles and documents
Synthesis and biological evaluation of pyrazolo[3,4-b]pyridin-4-ones as a new class of topoisomerase II inhibitors
Tabrizi, Mojgan Aghazadeh,Baraldi, Pier Giovanni,Baraldi, Stefania,Prencipe, Filippo,Preti, Delia,Saponaro, Giulia,Romagnoli, Romeo,Gessi, Stefania,Merighi, Stefania,Stefanelli, Angela,Fazzi, Debora,Borea, Pier Andrea,Maia, Rodolfo Couto,Romeiro, Nelilma C.,Fraga, Carlos A.M.,Barreiro, Eliezer J.
, p. 342 - 353 (2016/10/11)
A series of 1,3,6-triphenylpyrazolo[3,4-b]pyridin-4-one derivatives was designed, synthesized and evaluated for cytotoxic activity in A375 human melanoma and human erythroleukemia (HEL) cells. The new pyrazolopyridones displayed comparable activities to the antitumor compound etoposide. The inhibitory effect of compounds 17, 18, 27 and 32 against topoisomerase II-mediated cleavage activities was measured finding good correlation with the results obtained from MTS assay. Docking studies into bacterial topoisomerase II (DNA Gyrase), topoisomerase IIα and topoisomerase IIβ binding sites in the DNA binding interface were performed.
